Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
12.91 EUR | +0.34% |
|
+12.36% | -23.63% |
06-04 | ORPEA : Integrating the detailed FY23 figures | ![]() |
06-04 | Emeis: sale of real estate assets in Ireland | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.63% | 1.81B | B- | ||
+21.77% | 1.72B | - | C+ | |
+25.95% | 1.42B | B | ||
-26.52% | 1.37B | - | ||
+27.15% | 778M | - | B | |
-17.27% | 407M | B- | ||
+210.69% | 399M | - | D+ | |
-12.74% | 311M | - | - | |
+20.43% | 170M | B | ||
+38.03% | 90.06M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMEIS Stock
- Ratings EMEIS